JP Morgan Raises Merck Price Target to $165 Amid Overvaluation Concerns
On October 3, 2023, JP Morgan reaffirmed its Overweight rating on Merck & Co (MRK) while increasing its price target from $150.00 to $165.00. This 10% boost reflects growing optimism about the pharmaceutical giant's future performance, driven by its strong product pipeline and market leadership in healthcare.
Merck, with a market capitalization of approximately $345.54 billion, is a major player in drug manufacturing, known for products like Keytruda, which contributed to $65.0 billion in total sales in 2025. Despite this positive outlook, GuruFocus's GF Value™ estimates the stock is 15.8% overvalued, trading at $140.06 against an intrinsic value of $120.92.
The company's GF Score™ of 79/100 highlights its strong financial performance, particularly in profitability and growth. However, its momentum rank is weaker, suggesting limited upward price movement. Additionally, insider sell activity has totaled $29,977,909 over the past three months, which may indicate profit-taking or concerns among executives.
Investors should weigh these factors carefully, as the stock's high P/E ratio of 111.95 further emphasizes its overvaluation compared to its 5-year median P/E of 20.17. While 26 gurus hold shares of Merck, with 8 adding to their positions and 16 trimming holdings, the mixed activity underscores a cautious but generally positive sentiment.